Case Note & Summary
The case involved an appeal by a pharmaceutical manufacturer regarding the classification of its products, Bifuran Supplement, Neftin-50, and Neftin-200, for excise duty purposes under the Central Excises and Salt Act, 1944. The appellant contended that these products should be classified as animal feed supplements under Item 68, thus exempt from excise duty, while the authorities classified them as patent or proprietary medicines under Item 14-E. The Assistant Collector initially classified the products under Item 14-E, but this was overturned by the Collector of Central Excise (Appeals), who classified them under Item 68. The Tribunal later reversed this decision, classifying the products back under Item 14-E, citing their therapeutic use in preventing ailments in poultry. The Supreme Court, upon reviewing the case, found that Neftin-50 and Neftin-200, containing Furazolidone, were indeed patent and proprietary medicines as they were used for treatment and prevention of diseases in poultry. The court emphasized that the exemption notifications did not apply to products classified under Item 14-E, and thus the appellant's products remained liable for excise duty. Furthermore, the court dismissed the appellant's claims of discrimination, stating that the differences in treatment arose from varying interpretations by different excise authorities, not from intentional bias. The appeal was ultimately dismissed without costs.
Headnote
A) Excise Duty - Classification of Goods - Patent or Proprietary Medicines - Products containing Furazolidone classified under Item 14-E as they are used for treatment and prevention of ailments in poultry - Central Excises and Salt Act, 1944, Item 14-E - The court held that Neftin-50 and Neftin-200, containing Furazolidone, are patent and proprietary medicines chargeable to excise duty under Item 14-E, as they are used for therapeutic purposes (Paras 262E-G). B) Excise Duty - Exemption Notifications - Applicability of Exemption - Exemption under notification dated February 15, 1984 does not apply to products classified under Item 14-E - Central Excises and Salt Act, 1944, Item 68 - The court held that the exemption does not transfer products from Item 14-E to Item 68, thus Neftin-50 and Neftin-200 remain liable for excise duty (Paras 263F-H; 264A-B). C) Constitutional Law - Discrimination - Claim of Hostile Discrimination - No systematic discrimination found against the appellant compared to other manufacturers - Article 14 of the Constitution - The court held that the appellant cannot claim exemption based on alleged discrimination as it did not arise from intentional or systematic bias (Paras 264G-H; 265A-B).
Issue of Consideration
Whether Bifuran Supplement, Neftin-50, and Neftin-200 are chargeable to excise duty as patent or proprietary medicines or exempt as animal feed supplements.
Final Decision
The Supreme Court dismissed the appeal, affirming the classification of Neftin-50 and Neftin-200 as patent and proprietary medicines under Item 14-E, thus liable for excise duty. The court found no merit in the claims of discrimination and upheld the applicability of the excise duty as per the relevant notifications.
Law Points
- Excise duty classification
- patent or proprietary medicines
- animal feed supplements
- discrimination under Article 14
- Central Excises and Salt Act
- 1944
